NPPB and heart failure: While the enrolled patients demonstrated key indicators of advanced heart failure—including NYHA class III symptoms, LVEF <35%, elevated NT‐proBNP levels, and reduced 6MWD—the limited use of implantable cardioverter‐defibrillators (ICD) in this cohort reflects the specific clinical profile of the study population.